Determination of 2′-Fucosyllactose and Lacto-N-neotetraose in Infant Formula
Human milk oligosaccharides (HMO) are the third most abundant solid component of human milk. It is likely that they are responsible for at least some of the benefits experienced by breast-fed infants. Until recently HMO were absent from infant formula, but 2′-fucosyllactose (2′-FL) and lacto-N-neote...
Main Authors: | Sean Austin, Denis Cuany, Julien Michaud, Bernd Diehl, Begoña Casado |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2018-10-01
|
Series: | Molecules |
Subjects: | |
Online Access: | http://www.mdpi.com/1420-3049/23/10/2650 |
Similar Items
-
Safety of the extension of use of 2’‐fucosyllactose (2’‐FL) and lacto‐N‐neotetraose (LNnT) as novel foods in food supplements for infants pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2022-05-01) -
Formula supplementation with human and bovine milk oligosaccharides modulates blood IgG and T-helper cell populations, and ex vivo LPS-stimulated cytokine production in a neonatal preclinical model
by: Marcia H. Monaco, et al.
Published: (2023-12-01) -
Review of the Clinical Experiences of Feeding Infants Formula Containing the Human Milk Oligosaccharide 2′-Fucosyllactose
by: Elizabeth J. Reverri, et al.
Published: (2018-09-01) -
Growth, Tolerance, and Compliance of Infants Fed an Extensively Hydrolyzed Infant Formula with Added 2′-FL Fucosyllactose (2′-FL) Human Milk Oligosaccharide
by: Carlett Ramirez-Farias, et al.
Published: (2021-01-01) -
Safety of lacto‐N‐fucopentaose I/2’‐fucosyllactose (LNFP‐I/2’‐FL) mixture as a novel food pursuant to Regulation (EU) 2015/2283
by: EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), et al.
Published: (2023-12-01)